Cellectis (CLLS) Total Non-Current Liabilities (2014 - 2026)
Cellectis (CLLS) recorded quarterly Total Non-Current Liabilities of $94.8 million in Q1 2026, down 8.05% quarter-over-quarter from $103.1 million in Q4 2025, and up 11.08% on a YoY basis from $85.3 million in Q1 2025.
Cellectis (CLLS) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Cellectis' Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $94.8 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 11.08% year-over-year to $94.8 million; the TTM figure through Mar 2026 stood at $94.8 million (up 11.08% YoY), while the FY2025 annual figure was $103.1 million, up 19.51% from the prior year.
- Total Non-Current Liabilities was $94.8 million for Q1 2026 at Cellectis, down from $103.1 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $105.4 million in Q1 2024 to a low of $70.4 million in Q1 2023.
- Historically, Total Non-Current Liabilities has averaged $90.1 million across 5 years, with a median of $89.6 million in 2023.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities declined 24.91% in 2022, then surged 49.67% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $72.3 million in 2022, then soared by 30.65% to $94.4 million in 2023, then dropped by 8.67% to $86.2 million in 2024, then increased by 19.51% to $103.1 million in 2025, then fell by 8.05% to $94.8 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $94.8 million (Q1 2026), $103.1 million (Q4 2025), and $94.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | 94.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.77 Mn |
| Dec 31, 2025 | 103.07 Mn |
| Sep 30, 2025 | 93.99 Mn |
| Jun 30, 2025 | 89.42 Mn |
| Mar 31, 2025 | 85.31 Mn |
| Dec 31, 2024 | 86.24 Mn |
| Sep 30, 2024 | 100.80 Mn |
| Jun 30, 2024 | 98.90 Mn |
| Mar 31, 2024 | 105.45 Mn |
| Dec 31, 2023 | 94.43 Mn |
| Sep 30, 2023 | 89.63 Mn |
| Jun 30, 2023 | 89.07 Mn |
| Mar 31, 2023 | 70.45 Mn |
| Dec 31, 2022 | 72.28 Mn |
| Sep 30, 2022 | 80.94 Mn |
| Jun 30, 2022 | 85.08 Mn |
| Mar 31, 2022 | 91.80 Mn |
| Dec 31, 2021 | 96.25 Mn |
| Sep 30, 2021 | 101.14 Mn |
| Jun 30, 2021 | 103.80 Mn |